CRISPR-based Gene Editing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The cRISPR-based gene editing market size is projected to expand from USD 5.87 billion in 2025 and USD 6.65 billion in 2026 to USD 12.45 billion by 2031, registering a CAGR of 13.35% between 2026 to 2031. This report is Segmented by Offering (Products, Software, Services), Technology (Cas9, Cas12, Cas13, Base Editing, and More), Modality (Ex-Vivo, In-Vivo), Application (Therapeutic Dev, Drug Discovery, Preclinical Models, Diagnostics), End User (Pharma and Biotech, Academic Institutes, Cros, and More), Geography (North America, Europe, Asia-Pacific, and More). Forecasts are Provided in Value (USD).

Global CRISPR-based Gene Editing Market Trends and Insights

Accelerating Therapeutic Development For Genetic Disorders

The CRISPR-based gene editing market is moving beyond proof-of-concept and into a stage where clinical development is becoming more repeatable across multiple disease areas. CASGEVY’s 2025 commercial performance showed that approved CRISPR therapies can support real patient uptake and meaningful revenue generation, which matters because it narrows the gap between scientific validation and commercial execution. A May 2025 New England Journal of Medicine report described a patient-specific in vivo base-editing treatment for carbamoyl-phosphate synthetase 1 deficiency that was delivered within months of diagnosis, which showed how quickly development timelines can compress in high-need settings. That matters for the CRISPR-based gene editing market because faster movement from diagnosis to intervention can widen the future addressable population for severe inherited disorders. The same pattern also improves sponsor confidence that rare disease programs can progress with clearer development logic once a working regulatory and manufacturing path has been demonstrated. As a result, therapeutic development is no longer just a scientific frontier in the CRISPR-based gene editing market, because it now functions as the main engine behind future revenue expansion.

Clinical Validation Of CRISPR Based Cell And Gene Therapies

Clinical validation now spans ex-vivo cell therapy, in-vivo liver editing, and early RNA-targeting approaches, which gives the CRISPR-based gene editing market a broader evidence base than earlier gene therapy waves. Phase 1 data for CRISPR Therapeutics’ CTX310 showed a 73% mean ANGPTL3 reduction, a 55% triglyceride reduction, and a 49% LDL reduction after a single intravenous infusion, with few adverse events reported in the early dataset. Nexiguran ziclumeran also delivered rapid, deep, and durable serum TTR reductions in hereditary transthyretin amyloidosis with polyneuropathy, which added another human proof point for in-vivo editing in a clinically meaningful setting. In oncology, CRISPR-Cas9 knockout of CISH in tumor-infiltrating lymphocytes produced complete and ongoing responses in metastatic colorectal cancer in a Phase 1 study, which showed that durable anti-tumor activity is possible even in difficult solid tumors. Together, these results show that the CRISPR-based gene editing market is gaining validation across different editing settings rather than relying on one narrow clinical use case. They also show why commercial and regulatory expectations are shifting upward for later programs that now enter development behind a stronger body of human data.

Delivery Efficiency And Tissue Specific Uptake Limitations

Delivery remains the most important technical limit on how far the CRISPR-based gene editing market can expand beyond current liver-focused use cases. Lipid nanoparticles have supported hepatic editing programs, but delivery to the brain, heart, skeletal muscle, and hematopoietic stem cells outside ex-vivo settings remains much less mature, which restricts the near-term indication map. A 2025 review in Precision Medicine and Engineering also found that organ-specific delivery strategies continue to face biodistribution and immune clearance challenges, which shows that vector precision is still inadequate for many targets. rAAV-CRISPR delivery adds another layer of difficulty because Cas9-directed immune clearance can weaken treatment effect and force the use of transient immunosuppression protocols. These issues keep the CRISPR-based gene editing market segmented into a liver-led early in-vivo wave and a later non-hepatic expansion path. Until that delivery barrier improves, many programs will continue to favor ex-vivo settings where editing and quality control are easier to manage before reinfusion.

Other drivers and restraints analyzed in the detailed report include:

• Expansion Of Translational Workflows In Pharma And Biotech R&D
• Widening Use In Multiplex Screening And Functional Genomics Platforms
• Off Target Risk And Editing Fidelity Concerns

Segment Analysis

Products held 72.31% of the offering segment in 2025, which made them the largest current revenue pool inside the CRISPR-based gene editing market. That position reflects recurring demand for guide RNA synthesis, Cas protein enzymes, and delivery vectors across both research settings and clinical development workflows. Reagent demand is also being lifted by tighter quality expectations as more programs move closer to regulated therapeutic use. Synthego’s cGMP-grade gRNA solutions, which are produced under ISO 13485 certification and FDA GMP-compliant conditions, show how the reagent bar is moving upward for clinical-stage work. Services form the third offering pillar in the CRISPR-based gene editing market, spanning editing design, cell therapy manufacturing, and outsourced functional genomics support for sponsors that want to limit fixed investment.

Software and bioinformatics tools remain the smallest current offering segment, but they are projected to expand at 18.38% CAGR through 2031, which makes them the fastest-growing component of the CRISPR-based gene editing market. CRISPR-GPT, reported in Nature Biomedical Engineering in 2025, showed how agentic software can automate experiment design and data analysis, which lowers the expertise barrier for laboratories that lack deep computational resources. The July 2026 CRISPRi atlas in human iPSCs further showed that bioinformatics is no longer a downstream reporting layer, because it now supports high-scale interpretation within both academic and industrial settings. This shift matters because procurement in the CRISPR-based gene editing market is moving toward platforms that combine wet-lab editing capability with stronger computational decision support. Over time, that should narrow the revenue gap between products and software even if reagents remain the larger absolute category.

CRISPR-Cas9 held 52.24% of the technology segment in 2025, which keeps it as the anchor platform across the CRISPR-based gene editing market. Its lead comes from deep integration into ex-vivo cell therapy workflows and from its growing use in liver-directed in-vivo editing programs. Sponsors also continue to favor Cas9 because it carries the strongest clinical familiarity and the clearest regulatory precedent among commercial-stage editing systems. Base editing is progressing as an important adjacent platform, and its clinical roadmap has already drawn attention to manufacturing control requirements and later-stage trial design standards. That dynamic keeps Cas9 structurally dominant in the CRISPR-based gene editing market, while newer editors build validation through more selective clinical entry points.

CRISPR-Cas13 is the fastest-growing technology segment at 19.52% CAGR through 2031, which highlights how RNA targeting is creating a distinct growth lane inside the CRISPR-based gene editing market. SHERLOCK and DETECTR platforms offer attomolar sensitivity with results in 30 to 60 minutes, which gives CRISPR diagnostics a meaningful point-of-care position relative to PCR in time-sensitive or resource-constrained settings. Prime editing also entered first-in-human trial stages in 2026, although efficiency and delivery remain important barriers to wide adoption. AI-designed Cas variants such as OpenCRISPR-1 indicate that the future technology map will extend beyond the currently familiar Cas families. As a result, the CRISPR-based gene editing market is likely to keep a dual structure in which Cas9 supports scale today while newer editors expand the future application perimeter.

Complete Report Scope:

• By Offering
  • Products
  • Software And Bioinformatics Tools
  • Services
• By Technology
  • CRISPR-Cas9
  • CRISPR-Cas12
  • CRISPR-Cas13
  • Base Editing
  • Prime Editing
  • Epigenetic Editing
  • Other Technologies
• By Gene Editing Modality
  • Ex-Vivo Editing
  • In-Vivo Editing
• By Application
  • Therapeutic Development
  • Drug Discovery And Target Identification
  • Preclinical Model Development
  • Diagnostics
  • Other Applications
• By End User
  • Pharmaceutical And Biotechnology Companies
  • Academic And Research Institutes
  • Contract Research Organizations And CDMOs
  • Diagnostic Laboratories
  • Other End Users
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.62% of CRISPR-based gene editing market share in 2025, which kept it as the largest regional contributor in the current global structure. The region’s lead rests on deep biotechnology infrastructure, stronger financing access, established clinical trial networks, and a concentration of companies with late-stage or commercial CRISPR assets. CRISPR Therapeutics entered 2026 with approximately USD 2 billion in cash and multiple active clinical programs, which reinforces North America’s role as the deepest capital and pipeline base for the CRISPR-based gene editing market. Editas Medicine also planned first-in-human progress for EDIT-401 in 2026, which adds to the region’s in-vivo development momentum. The U.S. Patent and Trademark Office’s reaffirmation of the Broad Institute’s position in the CRISPR/Cas9 interference case also shows how intellectual property still shapes competitive positioning and licensing structures in the leading regional cluster.

Europe remains the second-largest regional block in the CRISPR-based gene editing market and continues to develop under the EMA’s Advanced Therapy Medicinal Products framework. The EMA granted CASGEVY PRIME designation and recommended 15-year long-term follow-up for genome-editing medicinal products, which has direct implications for development cost and timeline planning across the regional pipeline. The December 2025 agreement on major pharmaceutical legislation reform in the European Union signaled an intent to streamline advanced therapy governance and reduce uncertainty for developers entering the region. Germany and the United Kingdom remain the strongest national anchors, while France, Italy, Spain, and the rest of Europe are expanding as treatment center capacity and reimbursement pathways improve.

Asia-Pacific is projected to grow at 15.15% CAGR through 2031, which makes it the fastest-growing regional segment in the CRISPR-based gene editing market. China and Japan lead the region’s momentum through expanding clinical activity, domestic development capability, and policy structures that are becoming more relevant to advanced therapies. India, South Korea, and Australia also contribute growing academic activity and sponsored trial participation, which supports a broader regional base beyond the two leading national markets. The Middle East and Africa, led by GCC countries with high sickle cell disease and thalassemia burden, represent a demand-pull opportunity for approved CRISPR therapies as access pathways mature. South America, with Brazil and Argentina as the main anchors, remains in earlier adoption and is still shaped more by university research and sponsored clinical trial activity than by broad commercial penetration.

List of Companies Covered in this Report:

• Agilent Technologies
• Bio-Rad Laboratories
• Bio-Techne
• Caribou Biosciences
• CRISPR Therapeutics AG
• Danaher
• Editas Medicine, Inc.
• Genscript
• Integrated DNA Technologies
• Intellia Therapeutics, Inc.
• Merck
• New England Biolabs
• OriGene Technologies
• Prime Medicine, Inc.
• QIAGEN
• Synthego Corporation
• Takara Bio
• Thermo Fisher Scientific
• Twist Bioscience Corporation

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support